【レポートの概要（一部）】
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 10
2 Introduction 11
2.1 Inborn Gene or Chromosome Alterations Overview 11
3 Products under Development 12
3.1 Inborn Gene or Chromosome Alterations – Pipeline Products by Stage of Development 12
3.2 Inborn Gene or Chromosome Alterations – Pipeline Products by Territory 13
3.3 Inborn Gene or Chromosome Alterations – Pipeline Products by Regulatory Path 14
3.4 Inborn Gene or Chromosome Alterations – Pipeline Products by Estimated Approval Date 15
3.5 Inborn Gene or Chromosome Alterations – Ongoing Clinical Trials 16
4 Inborn Gene or Chromosome Alterations – Pipeline Products under Development by Companies 17
4.1 Inborn Gene or Chromosome Alterations Companies – Pipeline Products by Stage of Development 17
4.2 Inborn Gene or Chromosome Alterations – Pipeline Products by Stage of Development 20
5 Inborn Gene or Chromosome Alterations Companies and Product Overview 23
5.1 AC-Gen Reading Life S.L. Company Overview 23
5.1.1 AC-Gen Reading Life S.L. Pipeline Products & Ongoing Clinical Trials Overview 23
5.2 Admera Health, LLC Company Overview 24
5.2.1 Admera Health, LLC Pipeline Products & Ongoing Clinical Trials Overview 24
5.3 Agena Bioscience, Inc Company Overview 25
5.3.1 Agena Bioscience, Inc Pipeline Products & Ongoing Clinical Trials Overview 25
5.4 Ariosa Diagnostics, Inc. Company Overview 29
5.4.1 Ariosa Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 29
5.5 Atomic International Company Overview 30
5.5.1 Atomic International Pipeline Products & Ongoing Clinical Trials Overview 30
5.6 Baylor College of Medicine Company Overview 31
5.6.1 Baylor College of Medicine Pipeline Products & Ongoing Clinical Trials Overview 31
5.7 BCML GmbH Company Overview 33
5.7.1 BCML GmbH Pipeline Products & Ongoing Clinical Trials Overview 33
5.8 BioCeps (Inactive) Company Overview 34
5.8.1 BioCeps (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 34
5.9 CardioDx, Inc. Company Overview 35
5.9.1 CardioDx, Inc. Pipeline Products & Ongoing Clinical Trials Overview 35
5.10 Celera Corporation Company Overview 37
5.10.1 Celera Corporation Pipeline Products & Ongoing Clinical Trials Overview 37
5.11 Celula, Inc. Company Overview 41
5.11.1 Celula, Inc. Pipeline Products & Ongoing Clinical Trials Overview 41
5.12 Children’s Hospital Boston Company Overview 42
5.12.1 Children’s Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview 42
5.13 China Medical Technologies, Inc. Company Overview 45
5.13.1 China Medical Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 45
5.14 Da An Gene Co., Ltd. Company Overview 48
5.14.1 Da An Gene Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 48
5.15 Dana-Farber Cancer Institute, Inc. Company Overview 51
5.15.1 Dana-Farber Cancer Institute, Inc. Pipeline Products & Ongoing Clinical Trials Overview 51
5.16 Epinex Diagnostics Incorporated Company Overview 53
5.16.1 Epinex Diagnostics Incorporated Pipeline Products & Ongoing Clinical Trials Overview 53
5.17 Genentech, Inc. Company Overview 54
5.17.1 Genentech, Inc. Pipeline Products & Ongoing Clinical Trials Overview 54
5.18 German Cancer Research Center Company Overview 55
5.18.1 German Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 55
5.19 GILUPI Nanomedizin Company Overview 57
5.19.1 GILUPI Nanomedizin Pipeline Products & Ongoing Clinical Trials Overview 57
5.20 Hadassah Medical Center Company Overview 58
5.20.1 Hadassah Medical Center Pipeline Products & Ongoing Clinical Trials Overview 58
5.21 Helicos BioSciences Corporation Company Overview 59
5.21.1 Helicos BioSciences Corporation Pipeline Products & Ongoing Clinical Trials Overview 59
5.22 Illumina, Inc. Company Overview 60
5.22.1 Illumina, Inc. Pipeline Products & Ongoing Clinical Trials Overview 60
5.23 IntegraGen SA Company Overview 62
5.23.1 IntegraGen SA Pipeline Products & Ongoing Clinical Trials Overview 62
5.24 Interleukin Genetics, Inc. Company Overview 64
5.24.1 Interleukin Genetics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 64
5.25 JS Genetics Inc. Company Overview 66
5.25.1 JS Genetics Inc. Pipeline Products & Ongoing Clinical Trials Overview 66
5.26 Laboratory Corporation of America Holdings Company Overview 67
5.26.1 Laboratory Corporation of America Holdings Pipeline Products & Ongoing Clinical Trials Overview 67
5.27 Laval University Company Overview 69
5.27.1 Laval University Pipeline Products & Ongoing Clinical Trials Overview 69
5.28 LifeCodexx AG Company Overview 70
5.28.1 LifeCodexx AG Pipeline Products & Ongoing Clinical Trials Overview 70
5.29 Maastricht University Medical Center Company Overview 71
5.29.1 Maastricht University Medical Center Pipeline Products & Ongoing Clinical Trials Overview 71
5.30 Massachusetts Eye and Ear Infirmary Company Overview 72
5.30.1 Massachusetts Eye and Ear Infirmary Pipeline Products & Ongoing Clinical Trials Overview 72
5.31 Medical Research Council Company Overview 74
5.31.1 Medical Research Council Pipeline Products & Ongoing Clinical Trials Overview 74
5.32 Micromedic Technologies Ltd Company Overview 75
5.32.1 Micromedic Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview 75
5.33 Multiplicom N.V. Company Overview 76
5.33.1 Multiplicom N.V. Pipeline Products & Ongoing Clinical Trials Overview 76
5.34 Myriad Genetics, Inc. Company Overview 78
5.34.1 Myriad Genetics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 78
5.35 Natera, Inc. Company Overview 80
5.35.1 Natera, Inc. Pipeline Products & Ongoing Clinical Trials Overview 80
5.36 National University of Singapore Company Overview 85
5.36.1 National University of Singapore Pipeline Products & Ongoing Clinical Trials Overview 85
5.37 NewGene Ltd Company Overview 89
5.37.1 NewGene Ltd Pipeline Products & Ongoing Clinical Trials Overview 89
5.38 NX PharmaGen Inc. Company Overview 94
5.38.1 NX PharmaGen Inc. Pipeline Products & Ongoing Clinical Trials Overview 94
5.39 Paragon Medical, Inc. Company Overview 95
5.39.1 Paragon Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 95
5.40 Population Diagnostics Inc. Company Overview 96
5.40.1 Population Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview 96
5.41 Qiagen N.V. Company Overview 100
5.41.1 Qiagen N.V. Pipeline Products & Ongoing Clinical Trials Overview 100
5.42 Quantamerix Company Overview 102
5.42.1 Quantamerix Pipeline Products & Ongoing Clinical Trials Overview 102
5.43 Sapien Biosciences Company Overview 103
5.43.1 Sapien Biosciences Pipeline Products & Ongoing Clinical Trials Overview 103
5.44 Seegene, Inc. Company Overview 104
5.44.1 Seegene, Inc. Pipeline Products & Ongoing Clinical Trials Overview 104
5.45 Sequenom, Inc. Company Overview 106
5.45.1 Sequenom, Inc. Pipeline Products & Ongoing Clinical Trials Overview 106
5.46 Stanford University Company Overview 112
5.46.1 Stanford University Pipeline Products & Ongoing Clinical Trials Overview 112
5.47 The Johns Hopkins University Company Overview 114
5.47.1 The Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 114
5.48 The Sheba Medical Center Company Overview 115
5.48.1 The Sheba Medical Center Pipeline Products & Ongoing Clinical Trials Overview 115
5.49 The University of Utah Company Overview 116
5.49.1 The University of Utah Pipeline Products & Ongoing Clinical Trials Overview 116
5.50 TrovaGene, Inc. Company Overview 117
5.50.1 TrovaGene, Inc. Pipeline Products & Ongoing Clinical Trials Overview 117
5.51 University of Colorado Company Overview 121
5.51.1 University of Colorado Pipeline Products & Ongoing Clinical Trials Overview 121
5.52 University of Washington Company Overview 122
5.52.1 University of Washington Pipeline Products & Ongoing Clinical Trials Overview 122
5.53 VitaPath Genetics, Inc. Company Overview 123
5.53.1 VitaPath Genetics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 123
5.54 Xiamen Zeesan Biotech Co.,Ltd Company Overview 124
5.54.1 Xiamen Zeesan Biotech Co.,Ltd Pipeline Products & Ongoing Clinical Trials Overview 124
5.55 Yale University Company Overview 125
5.55.1 Yale University Pipeline Products & Ongoing Clinical Trials Overview 125
6 Inborn Gene or Chromosome Alterations- Recent Developments 126
7 Appendix 165
7.1 Methodology 165
7.2 About GlobalData 167
7.3 Contact Us 168
7.4 Disclaimer 168
【レポート販売概要】
■ タイトル：世界における先天的遺伝子変異または先天的染色体変異検査製品のパイプライン動向2015■ 英文：Inborn Gene or Chromosome Alterations - Pipeline Review, 2015
■ 発行日：2015年10月1日
■ 調査会社：GlobalData
■ 商品コード：GDME0076EPD
■ 調査対象地域：グローバル
- 腎性貧血(Renal Anemia)：世界の治験レビュー2014年下半期版Renal Anemia Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Renal Anemia Global Clinical Trials Review, H2, 2014" provides data on the Renal Anemia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Renal Anemia. It includes an overview of the trial numbers and their recruitment status as per the sit …
- ICT投資の優先順位：製薬産業部門- 企業のICT投資計画Why was the report written? In order to provide deeper insights into pharmaceutical companies’ ICT investment priorities and strategic objectives. What is the current market landscape and what is changing? Kable’s survey finds that apart from investing in core technologies (such as security, enterprise applications, and IT systems management), many pharmaceutical companies are looking to adopt gre …
- ハースの世界市場予測（～2023年）：暖炉、ストーブ、インサート“Increasing demand for esthetic home decor among customers is expected to drive the hearth market” The hearth market is expected to be valued at USD 15.72 billion in 2018 and is expected to reach USD 19.01 billion by 2023, at a CAGR of 3.87% between 2018 and 2023. On the basis of volume, the market is expected to register a shipment of 7.5 million units by 2023, at a CAGR of 6.22% during the forec …
- 甲殻類の世界市場2016-2020About Crustaceans There are approximately 40,000 crustacean species, including shrimp, lobsters, barnacles, crabs, krill, and other related species. The market for crustaceans is growing due to high consumption of seafood worldwide and rising global population. China accounts for 35% of all seafood consumed globally, and we estimate that by 2017, China will become the largest market for seafood gl …
- クメンの世界市場動向及び予測2015The present report is an essential resource for a one looking for detailed information on the world Cumene market. The report covers data on global, regional and national markets including present and future trends for supply and demand, prices, and downstream industries. In addition to the analytical part, the report provides a range of tables and figures which all together give a true insight in …
- スマートミラー（Smart Mirror）市場2013The objective of this report identifies and quantifies the opportunities, challenges, and prospects for growth of smart mirrors. Specifically, it analyzes the capabilities of current and likely future smart mirror technologies and how these technologies may be deployed in both automotive and non-automotive applications. Smart technologies covered in the report include the following: Self-dimming t …
- 世界の屋内位置情報ベース検索及び広告市場：小売、ホスピタリティ産業、ヘルスケア（医療）、航空産業About Indoor Location-based Search and Advertising The business scenario around the world is undergoing a huge paradigm shift. Location information has started to play an increasingly critical role in the way businesses operate. Brands are coming up with new innovative ways to engage and interact with consumers. Level of personalization offered is becoming the new means to gain competitive advanta …
- 脊髄外傷治療用デバイスの世界市場ABSTRACTAbout Spinal Trauma Devices Spinal trauma refers to a severe injury to the spinal cord. It can occur due to accidents, falls, violence like a gunshot, or infections and requires the fixation of spinal trauma devices to treat bone deformities, facilitate bone fusion, strengthen and stabilize the spinal cord, and prevent further damage and complications. Technavio’s analysts forecast the glo …
- 世界の大静脈フィルター市場2015The Global Inferior Vena Cava Filters (IVCF) Industry Report 2015 is a professional and in-depth study on the current state of the Inferior Vena Cava Filters (IVCF) industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Inferior Vena Cava Filters (IVCF) market analysis is provided for the international ma …
- Mobile Wallet: Location-based Commerce and Peer-to-Peer PaymentsWorld-wide, mobile commerce and peer-to-peer payments are in their infancy. While Japan and Korea are leading, France, Finland, and the U.K. are just moments behind. Key South American and Central American countries are exploring business process and market acceptance of mobile commerce. African nations, challenged by politics, have seen recent developments in peer-to-peer payments collapse while …
- 雲母の世界市場動向2014/2015The report presents a thorough study of mica, covering both global and regional markets. It aims to give a proper picture of the market, its trends, perspectives and opportunities. Comprehensive data showing mica worldwide production, consumption, trade statistics and prices are provided. Each country’s market overview covers the following: mica production in the country, major manufacturers, mica …
- 頭蓋内圧（ICP）モニタリング装置の世界市場分析：方法別（侵襲的、非侵襲的）、用途別（外傷性脳傷害、脳内出血、髄膜炎、くも膜下出血、その他）、セグメント予測、2014-2025The global intracranial pressure monitoring devices market is expected to reach USD 1.9 billion 2025, according to a new report by Grand View Research, Inc. Increasing neurological disorders and growing awareness regarding various treatment options available is spurring the growth of these devices on a global level. In addition, constant rise in patient numbers suffering from severe brain diseases …
- インターロイキン阻害剤の世界市場2019-2023Global Interleukin Inhibitors Market: About this market Technavio’s Interleukin inhibitors market analysis considers sales from Interleukin-23 inhibitors, Interleukin-17 inhibitors, Interleukin-6 inhibitors, and other Interleukin inhibitors. Our analysis also considers the sales of Interleukin inhibitors in Asia, Europe, North America, and ROW. In 2018, the Interleukin-23 inhibitors segment had a …
- 世界の広報活動用ツール市場動向（2012-2016）TechNavio's analysts forecast the Global Public Relations Tools market to grow at a CAGR of 5.10 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increased focus on digital media marketing. The Global Public Relations Tools market has also been witnessing the emergence of SaaS-based public relations solutions. However, the lack of effective commun …
- 防弾チョッキの世界市場2016-2020About Bullet Proof Vest A bulletproof vest, also known as a bullet-resistant vest or ballistic vest is a type of personal protective equipment. It is used by the military, law enforcement personals, and many times by civilians as a protective cover against bullets and shrapnel from explosions. Soft bulletproof vests weigh less and provide protection against small-caliber handguns. Hard bulletproof …
